Thomas Merten
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thomas Merten has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
Harald Merckelbach
Department of Clinical Psychological Science, Faculty of Psychology and Neuroscience, Maastricht University, the Netherlands
5 shared publicationsBrechje Dandachi-FitzGerald
Maastricht University
4 shared publications- Brechje Dandachi-FitzGerald
Faculty of Psychology, Open University, Heerlen, The Netherlands
3 shared publications - Esteban Puente-López
Department of Psychology, Universidad de Valladolid
3 shared publications Peter Giger
Formerly Department of Defence, Civil Protection and Sport, Bern, Switzerland
3 shared publicationsAndreas Stevens
Medizinisches Begutachtungsinstitut, Tübingen, Germany
2 shared publications
Latest Publications
- 1 March 2026
- Published by Hogrefe Publishing Group in Zeitschrift für Neuropsychologie
- Vol. 37 (1) , 5-17
Streuung der Reaktionszeiten (Alertness) als eingebetteter Beschwerdenvalidierungsindikator
Zusammenfassung: Im deutschen Sprachraum wird die Standardabweichung des Untertests Alertness aus der Testbatterie zur Aufmerksamkeitsprüfung als eingebetteter Beschwerdenvalidierungsindikator verwendet. Anhand einer Stichprobe von 224 Gutachtenproband_innen wurden durch eine Grenzwertoptimierungskurve Grenzwerte bei einer Spezifität von 90 % bestimmt. Sie lagen für die Testbedingungen (ohne/mit Warnton) bei >128 ms/>110 ms (Sensitivität: 49 %/53 %). Die Robustheit gegenüber genuinen kognitiven Störungen wurde anhand einer Stichprobe von 987 klinischen Patient_innen geprüft. Insbesondere bei Vorliegen erheblicher kognitiver Störungen war die Falsch-Positiv-Rate für beide Testbedingungen unvertretbar hoch (35.8 %/37.6 %). Die Ergebnisse demonstrieren zwar die Eignung des Alertness-Untertests zur Beschwerdenvalidierung im Gutachtenkontext, weisen aber gleichzeitig die Gefahr aus, dass Patient_innen mit genuinen kognitiven Störungen fälschlich als ungültig in ihren Testprofilen ausgewiesen werden können.
- 1 March 2026
- Published by Hogrefe Publishing Group in Zeitschrift für Neuropsychologie
- Vol. 37 (1) , 5-17
Streuung der Reaktionszeiten (Alertness) als eingebetteter Beschwerdenvalidierungsindikator
Zusammenfassung: Im deutschen Sprachraum wird die Standardabweichung des Untertests Alertness aus der Testbatterie zur Aufmerksamkeitsprüfung als eingebetteter Beschwerdenvalidierungsindikator verwendet. Anhand einer Stichprobe von 224 Gutachtenproband_innen wurden durch eine Grenzwertoptimierungskurve Grenzwerte bei einer Spezifität von 90 % bestimmt. Sie lagen für die Testbedingungen (ohne/mit Warnton) bei >128 ms/>110 ms (Sensitivität: 49 %/53 %). Die Robustheit gegenüber genuinen kognitiven Störungen wurde anhand einer Stichprobe von 987 klinischen Patient_innen geprüft. Insbesondere bei Vorliegen erheblicher kognitiver Störungen war die Falsch-Positiv-Rate für beide Testbedingungen unvertretbar hoch (35.8 %/37.6 %). Die Ergebnisse demonstrieren zwar die Eignung des Alertness-Untertests zur Beschwerdenvalidierung im Gutachtenkontext, weisen aber gleichzeitig die Gefahr aus, dass Patient_innen mit genuinen kognitiven Störungen fälschlich als ungültig in ihren Testprofilen ausgewiesen werden können.
- 5 July 2025
- Published by Elsevier in Current Opinion in Psychology
- Vol. 65, 102096
The self-report fallacy: When diagnosis predominantly relies on subjective symptom report
- 5 July 2025
- Published by Elsevier in Current Opinion in Psychology
- Vol. 65, 102096
The self-report fallacy: When diagnosis predominantly relies on subjective symptom report
- 12 March 2025
- Published by Grupo Editorial Psicofundación in Psicothema
- Vol. 37 (2) , 74-85
Prevalence of Symptom Overreporting in the Structured Inventory of Malingered Symptomatology (SIMS) in Clinical Patients: A Meta-Analysis
Background: Failure on symptom validity tests may occur in a variety of contexts and situations, including routine clinical settings. To date, no meta-analysis has targeted the failure rate of the Structured Inventory of Malingered Symptomatology (SIMS) in clinical assessments, nor the factors that may moderate this rate. Method: We used a binomial-normal random-effects meta-analysis to estimate the pooled failure rate of SIMS among patients with a clinical diagnosis who were evaluated in a non-forensic setting. Results: 34 studies and 40 samples were included. The total sample size was 8844 patients. The mean total SIMS score was 15.9 (SD = 5.2). The estimated overall failure rate of SIMS was 36% (95% CI: 30%-43%; I 2 = 96.6%, p < .001). Conclusions: There is an elevated failure rate on the SIMS in clinical patient populations; however, these positive results are not necessarily false positives. The methodological challenge to tell true and false positives apart appears to be of primary importance and should dictate both careful planning of future studies and circumspection when interpreting rates of validity test failure in clinical assessments.
- 12 March 2025
- Published by Grupo Editorial Psicofundación in Psicothema
- Vol. 37 (2) , 74-85
Prevalence of Symptom Overreporting in the Structured Inventory of Malingered Symptomatology (SIMS) in Clinical Patients: A Meta-Analysis
Background: Failure on symptom validity tests may occur in a variety of contexts and situations, including routine clinical settings. To date, no meta-analysis has targeted the failure rate of the Structured Inventory of Malingered Symptomatology (SIMS) in clinical assessments, nor the factors that may moderate this rate. Method: We used a binomial-normal random-effects meta-analysis to estimate the pooled failure rate of SIMS among patients with a clinical diagnosis who were evaluated in a non-forensic setting. Results: 34 studies and 40 samples were included. The total sample size was 8844 patients. The mean total SIMS score was 15.9 (SD = 5.2). The estimated overall failure rate of SIMS was 36% (95% CI: 30%-43%; I 2 = 96.6%, p < .001). Conclusions: There is an elevated failure rate on the SIMS in clinical patient populations; however, these positive results are not necessarily false positives. The methodological challenge to tell true and false positives apart appears to be of primary importance and should dictate both careful planning of future studies and circumspection when interpreting rates of validity test failure in clinical assessments.
- 7 March 2025
- Published by Taylor & Francis in Applied Neuropsychology: Adult
- p. 1-9
Detecting simulated symptoms in chronic pain and fibromyalgia: A two-study evaluation of the Italian version of the Self-Report Symptom Inventory
The subjective nature of pain complicates objective verification, often leading to noncredible symptom reports in compensable settings. Across two studies, we evaluated the Italian Self-Report Symptom Inventory (SRSI-It) in distinguishing healthy individuals, simulators, and fibromyalgia patients. In Study 1, we assigned 958 participants to the honest (n = 482) or simulator group (n = 476). Simulators reported higher scores on genuine and pseudosymptoms. A cut score > 6 showed 92% specificity and 64% sensitivity; > 9 raised specificity to 95%. The SRSI-It identified 62% and 58% of simulators at > 6 and > 9, respectively, compared to 76% identified by the SIMS. In Study 2, we recruited 100 patients and paired each with a healthy control and a fibromyalgia simulator (N = 300). Simulators scored highest on pseudosymptoms, while patients scored higher than controls. The SRSI-It identified 73% and 61% of simulators at cut scores of > 6 and > 9, compared to 51% and 34% of patients and 15% and 13% of controls. The SRSI-It demonstrated sensitivity to simulated pain, suggesting its utility in distinguishing simulators from honest respondents in clinical and forensic settings. However, caution is warranted to avoid misclassifying genuine patients, highlighting the need for complementary tools.
- 7 March 2025
- Published by Taylor & Francis in Applied Neuropsychology: Adult
- p. 1-9
Detecting simulated symptoms in chronic pain and fibromyalgia: A two-study evaluation of the Italian version of the Self-Report Symptom Inventory
The subjective nature of pain complicates objective verification, often leading to noncredible symptom reports in compensable settings. Across two studies, we evaluated the Italian Self-Report Symptom Inventory (SRSI-It) in distinguishing healthy individuals, simulators, and fibromyalgia patients. In Study 1, we assigned 958 participants to the honest (n = 482) or simulator group (n = 476). Simulators reported higher scores on genuine and pseudosymptoms. A cut score > 6 showed 92% specificity and 64% sensitivity; > 9 raised specificity to 95%. The SRSI-It identified 62% and 58% of simulators at > 6 and > 9, respectively, compared to 76% identified by the SIMS. In Study 2, we recruited 100 patients and paired each with a healthy control and a fibromyalgia simulator (N = 300). Simulators scored highest on pseudosymptoms, while patients scored higher than controls. The SRSI-It identified 73% and 61% of simulators at cut scores of > 6 and > 9, compared to 51% and 34% of patients and 15% and 13% of controls. The SRSI-It demonstrated sensitivity to simulated pain, suggesting its utility in distinguishing simulators from honest respondents in clinical and forensic settings. However, caution is warranted to avoid misclassifying genuine patients, highlighting the need for complementary tools.
- 27 February 2025
- Published by Taylor & Francis in The Clinical Neuropsychologist
- Vol. 39 (7) , 1996-2020
The risk of bias – symptom and performance validity (RoB-spv): A risk of bias checklist for systematic review and meta-analysis
Objective: The analysis of risk of bias in systematic reviews (SR) and meta-analyses (MA) is a fundamental task to ensure the correct synthesis of results. To carry out this task, specific tools must be used for each research design of the studies analyzed. The choice of an appropriate tool is currently a challenge for researchers developing SR and MA in the area of symptom and performance validity because the research designs used have been created specifically for this field. Although these designs can be integrated within the classic classifications, they present a number of particular characteristics that are not reflected in any of the current risk of bias analysis tools. The aim of this study is to design a checklist specifically for systematic review/meta-analysis focused on validity tests. Methods: The checklist was developed through objective review of the existing evidence, development of checklist items, and refinement by external feedback and performance analysis. Results: The checklist is composed of four sections: Clinical comparison group selection, sources of bias in either simulation or criterion group designs, and overall assessment of the study. Inter-rater reliability was assessed with a sample of 20 studies, resulting in good to excellent intraclass correlation coefficients for most items. Conclusions: The checklist seeks to fill an important gap in the literature by serving as an assessment tool that improves the reliability of evidence synthesis in symptom and performance validity studies. This instrument facilitates the development of SR and MA that meet international standards, improving methodological rigor and reliability in the forensic setting.
- 27 February 2025
- Published by Taylor & Francis in The Clinical Neuropsychologist
- Vol. 39 (7) , 1996-2020
The risk of bias – symptom and performance validity (RoB-spv): A risk of bias checklist for systematic review and meta-analysis
Objective: The analysis of risk of bias in systematic reviews (SR) and meta-analyses (MA) is a fundamental task to ensure the correct synthesis of results. To carry out this task, specific tools must be used for each research design of the studies analyzed. The choice of an appropriate tool is currently a challenge for researchers developing SR and MA in the area of symptom and performance validity because the research designs used have been created specifically for this field. Although these designs can be integrated within the classic classifications, they present a number of particular characteristics that are not reflected in any of the current risk of bias analysis tools. The aim of this study is to design a checklist specifically for systematic review/meta-analysis focused on validity tests. Methods: The checklist was developed through objective review of the existing evidence, development of checklist items, and refinement by external feedback and performance analysis. Results: The checklist is composed of four sections: Clinical comparison group selection, sources of bias in either simulation or criterion group designs, and overall assessment of the study. Inter-rater reliability was assessed with a sample of 20 studies, resulting in good to excellent intraclass correlation coefficients for most items. Conclusions: The checklist seeks to fill an important gap in the literature by serving as an assessment tool that improves the reliability of evidence synthesis in symptom and performance validity studies. This instrument facilitates the development of SR and MA that meet international standards, improving methodological rigor and reliability in the forensic setting.
- 5 February 2025
- Published by Springer Nature
- p. 821-828
Kognitive Beschwerdenvalidierungstests
- 5 February 2025
- Published by Springer Nature
- p. 829-837
Einzelfallexperimentelle Alternativwahlverfahren
- 5 February 2025
- Published by Springer Nature
- p. 829-837
Einzelfallexperimentelle Alternativwahlverfahren
- 28 January 2025
- Published by Springer Nature in Psychological Injury and Law
- Vol. 18 (1) , 35-48
Invalid Response Set, Malingering, and Related Base Rate in Psychological Injury I: Performance Validity Tests
- 28 January 2025
- Published by Springer Nature in Psychological Injury and Law
- Vol. 18 (1) , 35-48
Invalid Response Set, Malingering, and Related Base Rate in Psychological Injury I: Performance Validity Tests
- 26 January 2025
- Published by Springer Nature
- p. 547-577
International Perspectives on Psychological Injury and Law: Cross-Cultural Aspects of Symptom and Performance Validity Assessment
- 26 January 2025
- Published by Springer Nature
- p. 547-577
International Perspectives on Psychological Injury and Law: Cross-Cultural Aspects of Symptom and Performance Validity Assessment
- 29 December 2024
- Published by SAGE Publications in Assessment
- Vol. 32 (8) , 1226-1234
Highly Elevated Scores on the Beck Depression Inventory–Second Edition as an Indicator of Noncredible Symptom Report
Some recent studies have revived the approach of investigating extreme levels of self-reported depressive symptoms as indicative of gross exaggeration. While scores above 40 on the Beck Depression Inventory–Second Edition (BDI-II) were discussed as indicating exaggerated symptom claims, different cut scores for identifying noncredible responding are now being discussed. A consecutive sample of 242 patients referred for forensic psychological assessment (mean age: 46.0 years, 47.7% women) with full data sets on the BDI-II and the Structured Inventory of Malingered Symptomatology (SIMS) were assessed. Of all patients, 13.2% scored above 40 and BDI-II scores correlated with SIMS total scores at .62. For different SIMS cutoffs (>14, >16, >19, >23) used as criterion standard, optimal cut scores for the BDI-II were computed. When specificity was set at a minimum of 90%, sensitivity estimates were below 50% for all four SIMS levels. Extreme scores on the BDI-II should raise concern about the credibility of self-reported depressive symptom load. Diagnosis as well as severity estimates should not be based primarily on self-report instruments. To avoid significant risks of bias, the development of reliable cut scores for BDI-II elevations should be based on more studies with samples from diverse contexts.
- 29 December 2024
- Published by SAGE Publications in Assessment
- Vol. 32 (8) , 1226-1234
Highly Elevated Scores on the Beck Depression Inventory–Second Edition as an Indicator of Noncredible Symptom Report
Some recent studies have revived the approach of investigating extreme levels of self-reported depressive symptoms as indicative of gross exaggeration. While scores above 40 on the Beck Depression Inventory–Second Edition (BDI-II) were discussed as indicating exaggerated symptom claims, different cut scores for identifying noncredible responding are now being discussed. A consecutive sample of 242 patients referred for forensic psychological assessment (mean age: 46.0 years, 47.7% women) with full data sets on the BDI-II and the Structured Inventory of Malingered Symptomatology (SIMS) were assessed. Of all patients, 13.2% scored above 40 and BDI-II scores correlated with SIMS total scores at .62. For different SIMS cutoffs (>14, >16, >19, >23) used as criterion standard, optimal cut scores for the BDI-II were computed. When specificity was set at a minimum of 90%, sensitivity estimates were below 50% for all four SIMS levels. Extreme scores on the BDI-II should raise concern about the credibility of self-reported depressive symptom load. Diagnosis as well as severity estimates should not be based primarily on self-report instruments. To avoid significant risks of bias, the development of reliable cut scores for BDI-II elevations should be based on more studies with samples from diverse contexts.